Skip to content

Neuphoria Therapeutics Inc.

NEUP

CIK 0001191070

← back to feed
Revenue (TTM)
$15.65M
Q3 May 2026
Net Income (TTM)
$2.71M
+97.6% YoY Q3 May 2026
EPS Diluted (TTM)
$1.28
+98.8% YoY Q3 May 2026
Gross Margin
—
Q3 May 2026
Operating Margin
6.7%
Q3 May 2026
Net Margin
17.3%
Q3 May 2026
Free Cash Flow (TTM)
—
Q3 May 2026
Cash
$19.44M
Q3 May 2026
Total Debt
—
Q3 May 2026
Shares Outstanding
5.4M sh
Q3 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings